# US 2016/0257938 A1 · Reprogramming Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257938 A1
- Document ID: US20160257938A1
- Status: Published application
- Kind: A1
- Application number: 15/069,730
- Filed: 2016-03-14
- Published: 2016-09-08
- Earliest claimed: 2010-03-31
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Saiyong Zhu; Sheng Ding
- Web page: https://patentgrep.com/patent/US20160257938A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/73: Hydrolases (EC 3.)
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2506/094: from keratinocytes
- C12N 2506/28: from vascular endothelial cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.

## Claims

### Claim 1

A method of inducing a non-pluripotent mammalian cell into an induced pluripotent stem cell, the method comprising:
contacting the non-pluripotent cell with a compound that promotes glycolytic metabolism, a TGFβ receptor/ALK5 inhibitor, and a MEK inhibitor, under conditions sufficient to induce the cell to become a pluripotent stem cell, thereby inducing the non-pluripotent mammalian cell into an induced pluripotent stem cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound that promotes glycolytic metabolism enhances reprogramming when compared to without the compound.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound that promotes glycolytic metabolism is a glycolysis activator, a substrate for glycolysis, a glycolic intermediate or its metabolic precursors, a glucose uptake transporter activator, a mitochondrial respiration modulator, an oxidative phosphorylation inhibitor, or a hypoxia-inducible factor activator.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound that promotes glycolytic metabolism up-regulates key glycolytic genes comprising GLUT1, HK2, PFK1, and/or LDHA.

### Claim 5 (depends on 2)

The method of claim 2, wherein the compound that promotes glycolytic metabolism comprises F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxaloylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), or a PDK1 (3′-phosphoinositide-dependent kinase-1) activator.

### Claim 6 (depends on 5)

The method of claim 5, wherein the PDK1 activator is:
(a) an allosteric PDK1 activator; or
(b) (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (“PS48”), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (“PS08”), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio)acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (“12Z”), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (“13Z”).

### Claim 7 (depends on 1)

The method of claim 1, further comprising contacting the non-pluripotent cell with a histone deacetylase (HDAC) inhibitor.

### Claim 8 (depends on 1)

The method of claim 1, further comprising one or more of:
(a) introducing into the non-pluripotent cell a polynucleotide encoding an Oct4 polypeptide;
(b) introducing into the non-pluripotent cell a polynucleotide encoding a Klf-4 polypeptide; and
(c) introducing into the non-pluripotent cell a polynucleotide encoding a Sox-2 polypeptide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the contacting comprises:
(a) contacting the non-pluripotent cell with a compound that promotes glycolytic metabolism in the absence of a MEK inhibitor, followed by contacting the non-pluripotent cell with a compound that promotes glycolytic metabolism and a MEK inhibitor; or
(b) contacting the non-pluripotent cell with a compound that promotes glycolytic metabolism, a TGFβ receptor/ALK5 inhibitor, and a histone deacetylase (HDAC) inhibitor in the absence of a MEK inhibitor, followed by contacting the non-pluripotent cell with compound that promotes glycolytic metabolism, a TGFβ receptor/ALK5 inhibitor, a histone deacetylase (HDAC) inhibitor and a MEK inhibitor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the non-pluripotent cell is a human cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the non-pluripotent cell is a somatic cell, a progenitor cell, or a fully differentiated cell.

### Claim 12

A mixture comprising: mammalian cells, a compound that promotes glycolytic metabolism, and one or more of:
a TGFβ receptor/ALK5 inhibitor,
a MEK inhibitor, or
one or more exogenous transcription factors comprising one or more of Oct4, Klf4, and Sox2.

### Claim 13 (depends on 12)

The mixture of claim 12, wherein the compound that promotes glycolytic metabolism is a glycolysis activator, a substrate for glycolysis, a glycolic intermediate or its metabolic precursors, a glucose uptake transporter activator, a mitochondrial respiration modulator, an oxidative phosphorylation inhibitor, or a hypoxia-inducible factor activator.

### Claim 14 (depends on 12)

The mixture of claim 12, wherein the compound that promotes glycolytic metabolism up-regulates key glycolytic genes comprising GLUT1, HK2, PFK1, and/or LDHA.

### Claim 15 (depends on 12)

The mixture of claim 12, wherein the compound that promotes glycolytic metabolism comprises F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxaloylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), or a PDK1 (3′-phosphoinositide-dependent kinase-1) activator.

### Claim 16 (depends on 15)

The mixture of claim 15, wherein the PDK1 activator is:
(a) an allosteric PDK1 activator; or
(b) (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (“PS48”), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (“PS08”), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio)acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (“12Z”), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (“13Z”).

### Claim 17 (depends on 12)

The mixture of claim 12, wherein the mammalian cells are human cells.

### Claim 18 (depends on 12)

The mixture of claim 12, wherein the mammalian cells are somatic cells, progenitor cells, fully differentiated cells, non-pluripotent cells, or pluripotent cells.

### Claim 19 (depends on 12)

The mixture of claim 12, wherein the mammalian cells are isolated mammalian cells.
